a76df2f9_docrine_Cancer_Research___CFCF__Status
[Title] A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis [Phase] I [Conditions] Neuroendocrine Tumor [State] MD [Status] 
Not Recruiting
N o t R e c r u i t i n g
E n r o l l i n g